Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)
(2011) In Diabetes, Obesity and Metabolism 13(2). p.185-188- Abstract
- The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to... (More)
- The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1882637
- author
- Lindblad, U. ; Lindberg, Gunnar LU ; Månsson, Nils-Ove LU ; Ranstam, Jonas LU ; Tyrberg, Maria LU ; Jansson, S. ; Lindwall, K. ; Svärdh, Mona LU ; Kindmalm, L. and Melander, Arne LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- IFG, prevention, primary care, randomized trial, sulphonylurea, type 2, diabetes
- in
- Diabetes, Obesity and Metabolism
- volume
- 13
- issue
- 2
- pages
- 185 - 188
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000285753700010
- scopus:78650662421
- pmid:21199271
- ISSN
- 1462-8902
- DOI
- 10.1111/j.1463-1326.2010.01331.x
- language
- English
- LU publication?
- yes
- id
- ff19abea-a238-4878-b292-ccf4c9c990ca (old id 1882637)
- date added to LUP
- 2016-04-01 10:05:38
- date last changed
- 2024-01-06 07:21:36
@article{ff19abea-a238-4878-b292-ccf4c9c990ca,
abstract = {{The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.}},
author = {{Lindblad, U. and Lindberg, Gunnar and Månsson, Nils-Ove and Ranstam, Jonas and Tyrberg, Maria and Jansson, S. and Lindwall, K. and Svärdh, Mona and Kindmalm, L. and Melander, Arne}},
issn = {{1462-8902}},
keywords = {{IFG; prevention; primary care; randomized trial; sulphonylurea; type 2; diabetes}},
language = {{eng}},
number = {{2}},
pages = {{185--188}},
publisher = {{Wiley-Blackwell}},
series = {{Diabetes, Obesity and Metabolism}},
title = {{Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)}},
url = {{http://dx.doi.org/10.1111/j.1463-1326.2010.01331.x}},
doi = {{10.1111/j.1463-1326.2010.01331.x}},
volume = {{13}},
year = {{2011}},
}